Patents
Patents for C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof (291,526)
03/2009
03/31/2009US7511190 Expressing a polypeptide encoded by a preferred polynucleotide sequence in a plant and detecting at least one factor that is modulated by or interacts with such polypeptide
03/31/2009US7511129 Genetically engineered DNA transfer vector comprising a polynucleotide sequence that encodes a toxin comprising an insecticidal fragment
03/31/2009US7511126 Position-independent and tissue specific expression of a transgene in milk of transgenic animals
03/31/2009US7511124 immunoconjugate and duramycin-based compositions and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases; kits
03/31/2009US7511123 Binding to antigen; controlling concentration
03/31/2009US7511122 Monoclonal and chimeric antibodies that bind to lipoteichoic acid of Gram positive bacteria. The antibodies also bind to whole bacteria and enhance phagocytosis and killing of the bacteria in vitro and enhance protection from lethal; light and heavy chains comprising complementarity determining regions
03/31/2009US7511121 Polymeric immunoglobulin fusion proteins that target low-affinity Fcγreceptors
03/31/2009US7511095 Thioester-terminated water soluble polymers and method of modifying the N-terminus of a polypeptide therewith
03/31/2009US7511094 2-methylbutyraldehyde diethyl acetal end capped polyoxyethylene glycol; polyalkylene oxide, polyivnylpyrrolidone, polyvinyl alcohol, polyoxazoline etc. endcapped with polyetherpolyamine copolymers or oligomers covalently attached to diacetal tetramethylene group
03/31/2009US7511024 Factor VII or VIIA-like molecules
03/31/2009US7511019 Method for treating a human patient for coronary artery disease, comprising administering into one or more coronary vessels in a human patient in need of treatment for coronary artery disease an effective amount of a recombinant fibroblast
03/31/2009US7511018 Juvenile hemochromatosis gene (HFE2A) cleavage products and uses thereof
03/31/2009US7511017 Inhibiting apoptosis associated with HIV infection; immunoglobulin constant domain heterologous polypeptide; isolated nucleic acid encoding a human polypeptide, tumor necrosis factor receptor-5
03/31/2009US7511015 Ribosylated human neutrophil peptide-1or an ADP-ribosylated human neutrophil peptide-1; modified antimicrobial activity compared to alpha defensin lacking ADP-ribosylated or ribosylated residue; altered chemotaxis of T cells, altered neutrophil recruitment
03/31/2009US7511012 Myostatin binding agents
03/31/2009US7511011 Synthetic lipid mixtures for the preparation of a reconstituted surfactant
03/31/2009US7511009 Recombinant DNA of a gene having a DNA sequence or amino acid sequence; antitumor agents
03/31/2009US7510878 Bacillus thuringiensis gene with lepidopteran activity
03/31/2009US7510875 Methods for producing purified adenoviral vectors
03/31/2009US7510874 Stable cell lines expressing HERG1a and HERG1b
03/31/2009US7510872 Transgenic cell comprising adenoviral vector for use as gene delivery tool; tissue engineering heterologous gene expression; DNA vaccines
03/31/2009US7510870 STAT3 activated stem cell
03/31/2009US7510867 Expression may be controlled by a regulatory element along with a small polyadenylation signal; entire gene expression cassettes may be packaged into a viral vector, preferably an adeno-associated virus vector; five or six rod repeats; cysteine-rich domain; muscular dystrophy
03/31/2009US7510863 Nucleotide sequence coding single stranded RNA viral sequences for use in generation antibodies to prevent, treat and diagnose respiratory system disorders in poultry; veterinary medicine
03/31/2009US7510862 Nucleic acid comprising retroviral sequences for use as tools in generation of vaccines for prevention of viral diseases and infection; immunotherapy; viricides, antisense agents
03/31/2009US7510855 Comprises nucleotide sequences coding protein of urogenital system for identifying moduators for treatment of cell proliferative and metastatic disorders
03/31/2009US7510854 Using transgenic gramnegative bacteria as biorecator for fermentation of methione and lysine for use in medicine, cosmetics and animal feeds
03/31/2009US7510853 Exhibiting similarity to cytokine; isolated or recombinant polynucleotide encoding antigenic polypeptide of sequence 2
03/31/2009US7510847 Drug screening for compound having uricosuric regulating action by incubating a transformed cell expressing a recombinant protein with uric acid; and determining an uptake of uric acid; gout
03/31/2009US7510846 Assay employing human or rat GAL-R2 galanin receptor
03/31/2009US7510845 Using g protein coupled receptor to identifying modulator for use in treatment and prevention of pain; antinociceptive agents
03/31/2009US7510843 Use of a polypeptide for detecting, preventing or treating a pathological condition associated with a degenerative, neurological or autoimmune disease
03/31/2009US7510840 Method of inhibiting growth or survival of a cell by providing an anti-108P5H8 antibody
03/31/2009US7510835 Methods for identifying risk of breast cancer and treatments thereof
03/31/2009US7510831 Expression vector comprising nucleotide sequences coding phytase for use in transformation and expression in aspergillus; enhancing nutrient quality of animal feeds
03/31/2009US7510828 Therapy, prevention of viral infections; obtaining viron sample; incubation, monitoring, calibration: using antithrombin agent
03/31/2009US7510707 PAR, a novel marker gene for breast and prostate cancers
03/31/2009CA2494888C Substances for preventing and treating autoimmune diseases
03/31/2009CA2289961C A gene causative of rheumatoid arthritis, method for diagnosing rheumatoid arthritis, and method for identifying causative factors of rheumatoid arthritis
03/31/2009CA2210139C Immunogenic conjugate molecules
03/31/2009CA2066204C Cystic fibrosis gene
03/26/2009WO2009039414A2 Methods and compositions for detection of ehrlichia chaffeensis (vlpt)
03/26/2009WO2009039217A1 Medicaments for the treatment of coronary syndromes
03/26/2009WO2009038889A1 Fhbp- and lpxl1-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
03/26/2009WO2009038880A1 Novel e-selectin variant
03/26/2009WO2009038700A1 Diagnosis and treatment of cancer using cancer-testis antigens
03/26/2009WO2009038475A1 Systems for expression of heterologous proteins in m. capsulatus
03/26/2009WO2009038462A1 Use of aav replication machinery for improved protein production
03/26/2009WO2009037566A2 Hyaluronidase and method of use thereof
03/26/2009WO2009037502A1 Modified xylan production
03/26/2009WO2009037402A2 Hpiv-2 variants and medical applications thereof
03/26/2009WO2009037279A1 Plants with increased yield
03/26/2009WO2009037183A2 Cosmetic and/or pharmaceutical preparation containing nucleic acid for the induction of antimicrobial peptides in epithelia
03/26/2009WO2009036949A1 Hypoallergenic variants of the major allergen from betula verrucosa pollen
03/26/2009WO2009036842A1 Method for reducing the number of viruses and microorganisms in biological extracts containing solids, and extracts produced according to this method
03/26/2009WO2009036574A1 Method of reducing the effects of cytostatic drugs on bone marrow derived cells, and methods of screening
03/26/2009WO2009036510A1 Novel avian cytokines and genetic sequences encoding same
03/26/2009WO2009013020A3 Inhibitor of the met-receptor and its use
03/26/2009WO2009010874A3 Preprocalcitonin antigen t epitopes
03/26/2009WO2009003732A3 Peptides with high affinity for the prolactin receptor
03/26/2009WO2008157729A3 Methods for predicting three-dimensional structures for alpha helical membrane proteins and their use in design of selective ligands
03/26/2009WO2008157697A3 Copolymer assay
03/26/2009WO2008121437A3 Trophinin-binding peptides and uses thereof
03/26/2009WO2008112008A3 Sensor proteins and assay methods
03/26/2009WO2008109079A3 High purity peptides
03/26/2009WO2008104804A3 Proteins
03/26/2009WO2008097366A3 Metabolically engineered escherichia coli for enchanced production of sialic acid
03/26/2009WO2007008547A3 Sp35 antibodies and uses thereof
03/26/2009WO2005076972A3 Chimeric vegf peptides
03/26/2009WO2005017096A3 SPLICE VARIANTS OF ErbB LIGANDS, COMPOSITIONS AND USES THEREOF
03/26/2009WO2005014615A3 Self-assembling peptides incorporating modifications and methods of use thereof
03/26/2009WO2004096993A3 Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus
03/26/2009WO2004094651A3 Novel human polypeptides encoded by polynucleotides
03/26/2009WO2004093804A3 Human polypeptides encoded by polynucleotides and methods of their use
03/26/2009WO2004064612A3 Regulation of tgf-b signaling by tomoregulin
03/26/2009US20090083886 Transgenic plants with increased glycine-betaine
03/26/2009US20090083880 Modified plant defensin
03/26/2009US20090083877 Transcription Factors, DNA and Methods for Introduction of Value-Added Seed Traits and Stress Tolerance
03/26/2009US20090083863 p300 transgenic animal
03/26/2009US20090082551 Method, compositions and classification for tumor diagnostics and treatment
03/26/2009US20090082537 Four branched dendrimer-peg for conjugation to proteins and peptides
03/26/2009US20090082410 Constitutively translocating cell line
03/26/2009US20090082296 Mycobacterial antigens expressed during latency
03/26/2009US20090082289 Adenoviral vectors having a protein IX deletion
03/26/2009US20090082279 Treating a condition associated with breakdown of the blood brain barrier by administering a peptide antagonist of zonulin that binds to the zonula occludens receptor, especially in the brain, yet does not physiologically modulate the opening of mammalian tight junctions
03/26/2009US20090082276 Selective vpac2 receptor peptide agonists
03/26/2009US20090082275 Ob protein compositions and methods
03/26/2009US20090082274 Collections of repeat proteins comprising repeat modules
03/26/2009US20090082273 Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
03/26/2009US20090082272 pharmacokinetics; sustained release; cost efficiency; industrial scale
03/26/2009US20090082270 myostatin antagonist protein is substantially serum stable for a period of at least 24 hours; treating individuals with muscle wasting conditions and provides further insight into the regulation of myostatin gene expression; muscular disorders
03/26/2009US20090082269 Agent for ameliorating heavy metal-induced disorders, and medicinal composition, food and cosmetic containing the same
03/26/2009US20090082267 Prevention and Reduction of Blood Loss
03/26/2009US20090082265 Compositions and methods for treating diseases
03/26/2009US20090082264 123 Human Secreted Proteins
03/26/2009US20090082263 Drug and method for improving brain function
03/26/2009US20090082262 Processed human chemokines PHC-1 and PHC-2
03/26/2009US20090082261 Urea-containing peptides as inhibitors of viral replication
03/26/2009US20090082257 MalPEG-Hb conjugate- containing compositions for delivering carbon monoxide (CO) to cells
03/26/2009US20090081798 Protein S Functional Assay